Pulmonary Hypertension in Older Adults

Clinics in Chest Medicine

Volumn 28, Issue 4, 2007, Pages 717-733

  McArdle, John R ^a   Trow, Terence K ^a   Lerz, Kathryn ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AORTA STENOSIS; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE; DIASTOLIC DYSFUNCTION; HEART DISEASE; HUMAN; HYPOXEMIA; LUNG EMBOLISM; MITRAL VALVE DISEASE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SLEEP APNEA SYNDROME; SYSTOLIC DYSFUNCTION; THROMBOEMBOLISM; WORLD HEALTH ORGANIZATION;

AGED; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; PREVALENCE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 35448997002     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2007.08.006     Document Type: Review

References (158)

1. Lilienfeld D.E., and Rubin L.J. Mortality from primary pulmonary hypertension in the United States, 1979-1996. Chest 117 3 (2000) 796-800
2. Shapiro B.P., McGoon M.D., and Redfield M.M. Unexplained pulmonary hypertension in elderly patients. Chest 131 1 (2007) 94-100
3. Hyduk A., Croft J.B., Ayala C., et al. Pulmonary hypertension surveillance: United States, 1980-2002. MMWR Surveill Summ 54 5 (2005) 1-28
4. Rich S. How do we explain unexplained pulmonary hypertension in the elderly?. Chest 131 1 (2007) 5-6
5. Rich S., Chomka E., Hasara L., et al. The prevalence of pulmonary hypertension in the United States: adult population estimates obtained from measurements of chest roentgenograms from the NHANES II Survey. Chest 96 2 (1989) 236-241
6. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl (2004) 14S-34S
7. Trow T.K., and McArdle J.R. Diagnosis of pulmonary arterial hypertension. Clin Chest Med 28 1 (2007) 59-73 viii
8. Crausman R.S., and Lewin J.M. Pulmonary arterial hypertension in nonagenarians. J Am Geriatr Soc 43 10 (1995) 1177
9. Algeo S., Morrison D., Ovitt T., et al. Noninvasive detection of pulmonary hypertension. Clin Cardiol 7 3 (1984) 148-156
10. Al-Shaer M.H., Choueiri N.E., Correia M.L., et al. Effects of aging and atherosclerosis on endothelial and vascular smooth muscle function in humans. Int J Cardiol 109 2 (2006) 201-206
11. Marin J., and Rodriguez-Martinez M.A. Age-related changes in vascular responses. Exp Gerontol 34 4 (1999) 503-512
12. Moreau P., d'Uscio L.V., and Luscher T.F. Structure and reactivity of small arteries in aging. Cardiovasc Res 37 1 (1998) 247-253
13. Ames B.N., Shigenaga M.K., and Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 90 17 (1993) 7915-7922
14. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 5S-12S
15. Appelbaum L., Yigla M., Bendayan D., et al. Primary pulmonary hypertension in Israel: a national survey. Chest 119 6 (2001) 1801-1806
16. Dantzker D.R. Primary pulmonary hypertension: the American experience. Chest 105 2 Suppl (1994) 26S-28S
17. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 2 (1987) 216-223
18. Braman S.S., Eby E., Kuhn C., et al. Primary pulmonary hypertension in the elderly. Arch Intern Med 151 12 (1991) 2433-2438
19. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 9 (2006) 1023-1030
20. Phipps B., Wong B., Chang C.H., et al. Unexplained severe pulmonary hypertension in the older age group. Chest 84 4 (1983) 399-402
21. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 4 (1984) 580-587
22. Simonneau G., Fartoukh M., Sitbon O., et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114 3 Suppl (1998) 195S-199S
23. Rich S., Rubin L., Walker A.M., et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117 3 (2000) 870-874
24. Cioffi U., De Simone M., Pavoni G., et al. Pulmonary capillary hemangiomatosis in an asymptomatic elderly patient. Int Surg 84 2 (1999) 168-170
25. Schachna L., Wigley F.M., Chang B., et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124 6 (2003) 2098-2104
26. Chang B., Schachna L., White B., et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 33 2 (2006) 269-274
27. Chang B., Wigley F.M., White B., et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 30 11 (2003) 2398-2405
28. Kawut S.M., Taichman D.B., Archer-Chicko C.L., et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 2 (2003) 344-350
29. Koh E.T., Lee P., Gladman D.D., et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35 10 (1996) 989-993
30. MacGregor A.J., Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40 4 (2001) 453-459
31. Webb G., and Gatzoulis M.A. Atrial septal defects in the adult: recent progress and overview. Circulation 114 15 (2006) 1645-1653
32. Barst R.J., McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 40S-47S
33. Sanders C., Bittner V., Nath P.H., et al. Atrial septal defect in older adults: atypical radiographic appearances. Radiology 167 1 (1988) 123-127
34. Vongpatanasin W., Brickner M.E., Hillis L.D., et al. The Eisenmenger syndrome in adults. Ann Intern Med 128 9 (1998) 745-755
35. Cacoub P., Dorent R., Maistre G., et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 71 5 (1993) 448-450
36. Yoshibayashi M., Nishioka K., Nakao K., et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 84 6 (1991) 2280-2285
37. Campbell M. Natural history of atrial septal defect. Br Heart J 32 6 (1970) 820-826
38. Craig R.J., and Selzer A. Natural history and prognosis of atrial septal defect. Circulation 37 5 (1968) 805-815
39. Steele P.M., Fuster V., Cohen M., et al. Isolated atrial septal defect with pulmonary vascular obstructive disease: long-term follow-up and prediction of outcome after surgical correction. Circulation 76 5 (1987) 1037-1042
40. Vogel M., Berger F., Kramer A., et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 82 1 (1999) 30-33
41. Kidd L., Driscoll D.J., Gersony W.M., et al. Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 87 2 Suppl (1993) I38-I51
42. Leatham A., and Segal B. Auscultatory and phonocar-diographic signs of ventricular septal defect with left to-right shunt. Circulation 25 (1962) 318-327
43. Newburger J.W., Rosenthal A., Williams R.G., et al. Noninvasive tests in the initial evaluation of heart murmurs in children. N Engl J Med 308 2 (1983) 61-64
44. Landi F., Cipriani L., Cocchi A., et al. Ostium secundum atrial septal defect in the elderly. J Am Geriatr Soc 39 1 (1991) 60-63
45. Tikoff G., and Wilson J.F. Atrial septal defect in a nonagenarian. Chest 58 6 (1970) 628-630
46. Borow K.M., and Karp R. Atrial septal defect: lessons from the past, directions for the future. N Engl J Med 323 24 (1990) 1698-1700
47. Breyer R.H., Monson D.O., Ruggie N.T., et al. Atrial septal defect: repair in patients over thirty-five years of age. J Cardiovasc Surg (Torino) 20 6 (1979) 583-586
48. de Lezo J.S., Medina A., Romero M., et al. Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension. Am Heart J 144 5 (2002) 877-880
49. Hairston P., Parker E.F., Arrants J.E., et al. The adult atrial septal defect: results of surgical repair. Ann Surg 179 5 (1974) 799-804
50. Horvath K.A., Burke R.P., Collins Jr. J.J., et al. Surgical treatment of adult atrial septal defect: early and long-term results. J Am Coll Cardiol 20 5 (1992) 1156-1159
51. John Sutton M.G., Tajik A.J., and McGoon D.C. Atrial septal defect in patients ages 60 years or older: operative results and long-term postoperative follow-up. Circulation 64 2 (1981) 402-409
52. Konstantinides S., Geibel A., Olschewski M., et al. A comparison of surgical and medical therapy for atrial septal defect in adults. N Engl J Med 333 8 (1995) 469-473
53. Mattila S., Merikallio E., and Tala P. ASD in patients over 40 years of age. Scand J Thorac Cardiovasc Surg 13 1 (1979) 21-24
54. Miyaji K., Furuse A., Tanaka O., et al. Surgical repair for atrial septal defect in patients over 70 years of age. Jpn Heart J 38 5 (1997) 677-684
55. Nasrallah A.T., Hall R.J., Garcia E., et al. Surgical repair of atrial septal defect in patients over 60 years of age: long-term results. Circulation 53 2 (1976) 329-331
56. Paolillo V., Dawkins K.D., and Miller G.A. Atrial septal defect in patients over the age of 50. Int J Cardiol 9 2 (1985) 139-147
57. Reed W.A., and Dunn M.I. Long-term results of repair of atrial septal defects. Am J Surg 121 6 (1971) 724-727
58. Cohn L.H., Morrow A.G., and Braunwald E. Operative treatment of atrial septal defect: clinical and haemodynamic assessments in 175 patients. Br Heart J 29 5 (1967) 725-734
59. Magilligan Jr. D.J., Lam C.R., Lewis Jr. J.W., et al. Late results of atrial septal defect repair in adults. Arch Surg 113 11 (1978) 1245-1247
60. Murphy J.G., Gersh B.J., McGoon M.D., et al. Long-term outcome after surgical repair of isolated atrial septal defect: follow-up at 27 to 32 years. N Engl J Med 323 24 (1990) 1645-1650
61. Shah D., Azhar M., Oakley C.M., et al. Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical prospective study. Br Heart J 71 3 (1994) 224-227 [discussion: 228]
62. Ward C. Secundum atrial septal defect: routine surgical treatment is not of proven benefit. Br Heart J 71 3 (1994) 219-223
63. Attie F., Rosas M., Granados N., et al. Surgical treatment for secundum atrial septal defects in patients >40 years old: a randomized clinical trial. J Am Coll Cardiol 38 7 (2001) 2035-2042
64. Golbin J.M., and Krowka M.J. Portopulmonary hypertension. Clin Chest Med 28 1 (2007) 203-218 ix
65. Kawut S.M., Taichman D.B., Ahya V.N., et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 11 9 (2005) 1107-1111
66. Robalino B.D., and Moodie D.S. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 17 2 (1991) 492-498
67. Fix O.K., Bass N.M., De Marco T., et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 13 6 (2007) 875-885
68. Shapiro B.P., Nishimura R.A., McGoon M.D., et al. Diagnostic dilemmas: diastolic heart failure causing pulmonary hypertension and pulmonary hypertension causing diastolic dysfunction. Advances in Pulmonary Hypertension 5 (2006) 13-20
69. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 3 (2006) 251-259
70. Vasan R.S., and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101 17 (2000) 2118-2121
71. Zile M.R., Gaasch W.H., Carroll J.D., et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. Circulation 104 7 (2001) 779-782
72. Garcia M.J., Thomas J.D., and Klein A.L. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 32 4 (1998) 865-875
73. Zile M.R., Baicu C.F., and Gaasch W.H. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 19 (2004) 1953-1959
74. Owan T.E., and Redfield M.M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47 5 (2005) 320-332
75. Capomolla S., Febo O., Guazzotti G., et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 19 5 (2000) 426-438
76. Benza R.L., and Tallaj J.A. Pulmonary hypertension out of proportion to left heart disease. Advances in Pulmonary Hypertension 5 (2006) 21-29
77. Moraes D.L., Colucci W.S., and Givertz M.M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102 14 (2000) 1718-1723
78. Louie E.K., Rich S., and Brundage B.H. Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. J Am Coll Cardiol 8 6 (1986) 1298-1306
79. Stojnic B.B., Brecker S.J., Xiao H.B., et al. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. Br Heart J 68 1 (1992) 16-20
80. Tutar E., Kaya A., Gulec S., et al. Echocardiographic evaluation of left ventricular diastolic function in chronic cor pulmonale. Am J Cardiol 83 9 (1999) 1414-1417
81. Little W.C., Badke F.R., and O'Rourke R.A. Effect of right ventricular pressure on the end-diastolic left ventricular pressure-volume relationship before and after chronic right ventricular pressure overload in dogs without pericardia. Circ Res 54 6 (1984) 719-730
82. Aurigemma G.P., and Gaasch W.H. Clinical practice: diastolic heart failure. N Engl J Med 351 11 (2004) 1097-1105
83. Solomon S.D., Janardhanan R., Verma A., et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369 9579 (2007) 2079-2087
84. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 9386 (2003) 777-781
85. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 1 (1997) 44-54
86. Farber H.W., Graven K.K., Kokolski G., et al. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 26 5 (1999) 1195-1196
87. Abramson S.V., Burke J.F., Kelly Jr. J.J., et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 116 11 (1992) 888-895
88. Dini F.L., Nuti R., Barsotti L., et al. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography 19 6 (2002) 457-465
89. Enriquez-Sarano M., Rossi A., Seward J.B., et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 29 1 (1997) 153-159
90. Teerlink J.R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?. J Card Fail 8 3 (2002) 124-127
91. Packer M., McMurray J., Massie B.M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11 1 (2005) 12-20
92. Bocchi E.A., Guimaraes G., Mocelin A., et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106 9 (2002) 1097-1103
93. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127 5 (2005) 1647-1653
94. Bonow R.O., Carabello B.A., Kanu C., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Developed in collaboration with the Society of Cardiovascular Anesthesiologists. Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114 5 (2006) e84-e231
95. Walston A., Peter R.H., Morris J.J., et al. Clinical implications of pulmonary hypertension in mitral stenosis. Am J Cardiol 32 5 (1973) 650-655
96. Schwammenthal E., Vered Z., Agranat O., et al. Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study. Circulation 102 19 (2000) 2378-2384
97. Ha J.W., Chung N., Jang Y., et al. Is the left atrial v. wave the determinant of peak pulmonary artery pressure in patients with pure mitral stenosis?. Am J Cardiol 85 8 (2000) 986-991
98. Okay T., Deligonul U., Sancaktar O., et al. Contribution of mitral valve reserve capacity to sustained symptomatic improvement after balloon valvulotomy in mitral stenosis: implications for restenosis. J Am Coll Cardiol 22 6 (1993) 1691-1696
99. Fawzy M.E. Percutaneous mitral balloon valvotomy. Catheter Cardiovasc Interv 69 2 (2007) 313-321
100. Fawzy M.E., Hassan W., Stefadouros M., et al. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis 13 6 (2004) 942-947 [discussion: 947-8]
101. Singh J.P., Evans J.C., Levy D., et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83 6 (1999) 897-902
102. Ward C., and Hancock B.W. Extreme pulmonary hypertension caused by mitral valve disease: natural history and results of surgery. Br Heart J 37 1 (1975) 74-78
103. Cesnjevar R.A., Feyrer R., Walther F., et al. High-risk mitral valve replacement in severe pulmonary hypertension: 30 years experience. Eur J Cardiothorac Surg 13 4 (1998) 344-351 [discussion: 351-2]
104. Foltz B.D., Hessel II E.A., and Ivey T.D. The early course of pulmonary artery hypertension in patients undergoing mitral valve replacement with cardioplegic arrest. J Thorac Cardiovasc Surg 88 2 (1984) 238-247
105. Yang H., Davidson Jr. W.R., Chambers C.E., et al. Preoperative pulmonary hypertension is associated with postoperative left ventricular dysfunction in chronic organic mitral regurgitation: an echocardiographic and hemodynamic study. J Am Soc Echocardiogr 19 8 (2006) 1051-1055
106. Cevese P.G., Gallucci V., Valfre C., et al. Pulmonary hypertension in mitral valve surgery. J Cardiovasc Surg (Torino) 21 1 (1980) 7-10
107. Salzberg S.P., Filsoufi F., Anyanwu A., et al. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 80 2 (2005) 502-506
108. Silver K., Aurigemma G., Krendel S., et al. Pulmonary artery hypertension in severe aortic stenosis: incidence and mechanism. Am Heart J 125 1 (1993) 146-150
109. Aragam J.R., Folland E.D., Lapsley D., et al. Cause and impact of pulmonary hypertension in isolated aortic stenosis on operative mortality for aortic valve replacement in men. Am J Cardiol 69 16 (1992) 1365-1367
110. Malouf J.F., Enriquez-Sarano M., Pellikka P.A., et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 40 4 (2002) 789-795
111. Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 2 (2005) 189-194
112. Fell C.D., and Martinez F.J. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 131 3 (2007) 641-643
113. Hamada K., Nagai S., Tanaka S., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131 3 (2007) 650-656
114. Lettieri C.J., Nathan S.D., Barnett S.D., et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129 3 (2006) 746-752
115. Oswald-Mammosser M., Weitzenblum E., Quoix E., et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 107 5 (1995) 1193-1198
116. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167 5 (2003) 735-740
117. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 9337 (2002) 895-900
118. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 2 (1999) 600-607
119. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med 9 5 (2003) 426-430
120. Bixler E.O., Vgontzas A.N., Ten Have T., et al. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med 157 1 (1998) 144-148
121. Fleury B. Sleep apnea syndrome in the elderly. Sleep 15 6 Suppl (1992) S39-S41
122. Hoch C.C., Reynolds III C.F., Monk T.H., et al. Comparison of sleep-disordered breathing among healthy elderly in the seventh, eighth, and ninth decades of life. Sleep 13 6 (1990) 502-511
123. Launois S.H., Pepin J.L., and Levy P. Sleep apnea in the elderly: a specific entity?. Sleep Med Rev 11 2 (2007) 87-97
124. Tishler P.V., Larkin E.K., Schluchter M.D., et al. Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 289 17 (2003) 2230-2237
125. Zamarron C., Gude F., Otero Y., et al. Prevalence of sleep disordered breathing and sleep apnea in 50- to 70-year-old individuals: a survey. Respiration 66 4 (1999) 317-322
126. Atwood Jr. C.W., McCrory D., Garcia J.G., et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl (2004) 72S-77S
127. Becattini C., Agnelli G., Pesavento R., et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 130 1 (2006) 172-175
128. Miniati M., Monti S., Bottai M., et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 85 5 (2006) 253-262
129. Pengo V., Lensing A.W., Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 22 (2004) 2257-2264
130. Tapson V.F., and Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 3 7 (2006) 564-567
131. Morris T.A., Marsh J.J., Chiles P.G., et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173 11 (2006) 1270-1275
132. Morris T.A., Marsh J.J., Chiles P.G., et al. Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension. Thromb Res 119 2 (2007) 257-259
133. Bonderman D., Jakowitsch J., Adlbrecht C., et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93 3 (2005) 512-516
134. Kuypers F.A., Yuan J., Lewis R.A., et al. Membrane phospholipid asymmetry in human thalassemia. Blood 91 8 (1998) 3044-3051
135. Lang I., and Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 7 (2006) 568-570
136. Tscholl D., Langer F., Wendler O., et al. Pulmonary thromboendarterectomy: risk factors for early survival and hemodynamic improvement. Eur J Cardiothorac Surg 19 6 (2001) 771-776
137. Kim N.H. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 7 (2006) 584-588
138. Peacock A., Simonneau G., and Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 7 (2006) 608-614
139. Widera E., and Sulica R. Pulmonary artery sarcoma misdiagnosed as chronic thromboembolic pulmonary hypertension. Mt Sinai J Med 72 6 (2005) 360-364
140. Wilson M.K., Granger E.K., and Preda V.A. Pulmonary hypertension due to isolated metastatic squamous cell carcinoma thromboemboli. Heart Lung Circ 15 2 (2006) 143-145
141. Malani A.K., Gupta C., Kutty A.V., et al. Pulmonary tumor thrombotic microangiopathy from metastatic gallbladder carcinoma: an unusual cause of severe pulmonary hypertension. Dig Dis Sci 52 2 (2007) 555-557
142. Nakamura H., Adachi H., Sudoh A., et al. Subacute cor pulmonale due to tumor embolism. Intern Med 43 5 (2004) 420-422
143. Stucki A., Kruse A., Iff S., et al. A rare cause of fatal right heart failure. Eur J Intern Med 17 1 (2006) 68-70
144. Roberts K.E., Hamele-Bena D., Saqi A., et al. Pulmonary tumor embolism: a review of the literature. Am J Med 115 3 (2003) 228-232
145. Shiue S.T., and McNally D.P. Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis. Arch Intern Med 148 3 (1988) 687-689
146. Waldhorn R.E., Tsou E., Smith F.P., et al. Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 12 6 (1984) 394-396
147. Coates G.G., Eisenberg B., and Dail D.H. Tc-99m sulfur colloid demonstration of diffuse pulmonary interstitial extramedullary hematopoiesis in a patient with myelofibrosis: a case report and review of the literature. Clin Nucl Med 19 12 (1994) 1079-1084
148. Garcia-Manero G., Schuster S.J., Patrick H., et al. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 60 2 (1999) 130-135
149. Marvin K.S., and Spellberg R.D. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 103 2 (1993) 642-644
150. Rumi E., Passamonti F., Boveri E., et al. Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. Am J Hematol 81 2 (2006) 124-127
151. Steensma D.P., Hook C.C., Stafford S.L., et al. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 118 3 (2002) 813-816
152. Weinschenker P., Kutner J.M., Salvajoli J.V., et al. Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol 69 4 (2002) 277-280
153. Bhatia S., Morrison J.F., Bower T.C., et al. Pulmonary hypertension in the setting of acquired systemic arteriovenous fistulas. Mayo Clin Proc 78 7 (2003) 908-912
154. Tayyareci G., Dayi S.U., Akgoz H., et al. A rare case of pulmonary hypertension as a result of arteriovenous fistula after cardiac surgery. Int Heart J 46 3 (2005) 551-556
155. Petrone K., and Katz P. Approaches to appropriate drug prescribing for the older adult. Prim Care 32 3 (2005) 755-775
156. Muirhead G.J., Wilner K., Colburn W., et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 53 Suppl 1 (2002) 21S-30S
157. Zusman R.M., Morales A., Glasser D.B., et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83 5A (1999) 35C-44C
158. van Giersbergen P.L., Treiber A., Clozel M., et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71 4 (2002) 253-262